Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $92.00 at HC Wainwright

Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT) had its target price upped by investment analysts at HC Wainwright from $75.00 to $92.00 in a research report issued on Monday, March 12th, Marketbeat.com reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 28.24% from the company’s current price.

Other equities research analysts have also issued reports about the company. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price target for the company. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Oppenheimer reaffirmed a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Nomura increased their price target on Sarepta Therapeutics to $96.00 and gave the company a “buy” rating in a report on Friday, March 2nd. Finally, Credit Suisse Group set a $81.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Friday, March 2nd. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $78.87.

Sarepta Therapeutics stock opened at $71.74 on Monday. The firm has a market capitalization of $4,805.80, a P/E ratio of -43.74 and a beta of 1.29. Sarepta Therapeutics has a 52 week low of $28.14 and a 52 week high of $84.37. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The business had revenue of $57.30 million during the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The business’s revenue for the quarter was up 961.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.71) earnings per share. research analysts predict that Sarepta Therapeutics will post -1.18 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock valued at $349,773,000 after purchasing an additional 58,433 shares in the last quarter. Fred Alger Management Inc. boosted its stake in Sarepta Therapeutics by 10.5% during the 4th quarter. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company’s stock valued at $87,996,000 after purchasing an additional 149,712 shares in the last quarter. Jennison Associates LLC boosted its stake in Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after purchasing an additional 6,357 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock valued at $49,858,000 after purchasing an additional 207,810 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in Sarepta Therapeutics by 63.4% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after purchasing an additional 338,737 shares in the last quarter. 84.98% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $92.00 at HC Wainwright” was posted by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/2018/04/07/sarepta-therapeutics-srpt-price-target-raised-to-92-00/2038416.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.